menu

ReachMD

Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

BCMA Who and When: Immunotherapies in Patients with RRMM

Play along in aninteractive live symposium & digital broadcast to improve your knowledge and refine your skills in RRMM medical management decisions.

Live Meeting
1.50 available credits
Information
June 04, 2022
06:30 PM - 08:30 PM CDT
International Ballroom North at the Hilton Chicago
720 S. Michigan Avenue, Chicago, Illinois, United States
ReachMD Healthcare Image
Details
Presenters
Related
Comments

  • Overview

    Who wants to put their skills to the test? Using a novel gamified approach, satellite attendees will challenge their knowledge and competency while learning from experts in relapsed/refractory multiple myeloma (RRMM). The symposium will be simulcast on Facebook Live, and an enduring program will be recorded immediately following the activity. A mobile phone-based audience response system will be used so all attendees, live and digital, can participate in real time.

    Click Here to Download Slide Presentation

  • Program Schedule*

    6:30–7:00 pm cst

    Registration and Dinner

    7:00–7:10 pm cst

    Welcome and Introduction

    • Welcome
    • Introduce BCMA as a viable target
    • Introduce currently available BCMA-directed therapies

    Saad Usmani, MD

    7:10–7:25 pm cst

    Leveraging Community Partnerships to Optimize BCMA-Directed Therapies

    • Belantamab mafodotin
    • CAR T-cell therapies: Ide-cel, cilta-cel

    Discussion to include: patient eligibility, efficacy and safety, community partnerships, logistical planning

    Saad Usmani, MD (Moderator)

    Sikander Ailawadhi, MD

    Amrita Krishnan, MD

    7:25–7:35 pm cst

    The Nuts and Bolts of Bispecific Antibodies

    • MOA
    • Targets
    • Similarities and differences with CAR T-cell therapy

    Amrita Krishnan, MD

    7:35–7:45 pm cst

    Preparing for Future T Cell Redirecting Therapy with Bispecific Antibodies

    • Current clinical trial data

    Saad Usmani, MD

    7:45–7:55 pm cst

    Panel Discussion: How bispecific antibodies may impact practice

    Saad Usmani, MD (Moderator)

    Sikander Ailawadhi, MD

    Amrita Krishnan, MD

    7:55–8:05 pm cst

    Addressing Access to Care in MM

    • Current disparities in MM Care
    • Access to clinical trials

    Sikander Ailawadhi, MD

    8:05–8:15 pm cst

    Panel discussion: Strategies to address diversity and inclusion in clinical trials

    Saad Usmani, MD (Moderator)

    Sikander Ailawadhi, MD

    Amrita Krishnan, MD

    8:15–8:25 pm cst

    Question and Answer

    Saad Usmani, MD (Moderator)

    Sikander Ailawadhi, MD

    Amrita Krishnan, MD

    8:25–8:30 pm cst

    Closing remarks

    Saad Usmani, MD

    *Subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Saad Z. Usmani, MD, MBA, FACP
    Chief of the Myeloma Service
    Memorial Sloan Kettering Cancer Center (MSK)
    Charlotte, NC

    Faculty:
    Sikander Ailawadhi, MD
    Professor of Medicine
    Division of Hematology-Oncology
    Mayo Clinic, Jacksonville FL 

    Amrita Krishnan, MD
    Director of Judy and Bernard Briskin Multiple Myeloma Center
    Professor of Hematology/Hematopoietic Cell Transplantation
    Duarte, CA

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Sara Fagerlie, PHD, CHCP, has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Anna Trentini has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the mechanism of action and relevant targets for bispecific antibodies
    • Interpret results from clinical trials evaluating the treatment of relapsed/refractory multiple myeloma (RRMM) with bispecific antibodies
    • Describe mitigation strategies for bispecific antibody-related adverse events
    • Recognize outcomes for patients with triple-class refractory multiple myeloma (MM)
    • Address disparities in access to novel MM treatments
    • Identify patients who are candidates for immunotherapies
    • Mange treatment-related adverse events for patients undergoing therapy for multiple myeloma

  • Target Audience

    This activity is designed to meet the educational needs of community and academic medical oncologists, hematologist oncologists, and other healthcare professionals who manage patients with hematologic malignancies in the United States.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Live Satellite Symposium activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This event is organized by Prova Education, accredited by Global Learning Collaborative, Inc., and is supported by an educational grant provided by Janssen Biotech Inc., administered by Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Presenters

Related

  • ASCO MM

    BCMA Who and When: Immunotherapies in Patients with RRMM

    Show more

Facebook Comments

Details
Presenters
Related
Comments
Recommended

  • Overview

    Who wants to put their skills to the test? Using a novel gamified approach, satellite attendees will challenge their knowledge and competency while learning from experts in relapsed/refractory multiple myeloma (RRMM). The symposium will be simulcast on Facebook Live, and an enduring program will be recorded immediately following the activity. A mobile phone-based audience response system will be used so all attendees, live and digital, can participate in real time.

    Click Here to Download Slide Presentation

  • Program Schedule*

    6:30–7:00 pm cst

    Registration and Dinner

    7:00–7:10 pm cst

    Welcome and Introduction

    • Welcome
    • Introduce BCMA as a viable target
    • Introduce currently available BCMA-directed therapies

    Saad Usmani, MD

    7:10–7:25 pm cst

    Leveraging Community Partnerships to Optimize BCMA-Directed Therapies

    • Belantamab mafodotin
    • CAR T-cell therapies: Ide-cel, cilta-cel

    Discussion to include: patient eligibility, efficacy and safety, community partnerships, logistical planning

    Saad Usmani, MD (Moderator)

    Sikander Ailawadhi, MD

    Amrita Krishnan, MD

    7:25–7:35 pm cst

    The Nuts and Bolts of Bispecific Antibodies

    • MOA
    • Targets
    • Similarities and differences with CAR T-cell therapy

    Amrita Krishnan, MD

    7:35–7:45 pm cst

    Preparing for Future T Cell Redirecting Therapy with Bispecific Antibodies

    • Current clinical trial data

    Saad Usmani, MD

    7:45–7:55 pm cst

    Panel Discussion: How bispecific antibodies may impact practice

    Saad Usmani, MD (Moderator)

    Sikander Ailawadhi, MD

    Amrita Krishnan, MD

    7:55–8:05 pm cst

    Addressing Access to Care in MM

    • Current disparities in MM Care
    • Access to clinical trials

    Sikander Ailawadhi, MD

    8:05–8:15 pm cst

    Panel discussion: Strategies to address diversity and inclusion in clinical trials

    Saad Usmani, MD (Moderator)

    Sikander Ailawadhi, MD

    Amrita Krishnan, MD

    8:15–8:25 pm cst

    Question and Answer

    Saad Usmani, MD (Moderator)

    Sikander Ailawadhi, MD

    Amrita Krishnan, MD

    8:25–8:30 pm cst

    Closing remarks

    Saad Usmani, MD

    *Subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Saad Z. Usmani, MD, MBA, FACP
    Chief of the Myeloma Service
    Memorial Sloan Kettering Cancer Center (MSK)
    Charlotte, NC

    Faculty:
    Sikander Ailawadhi, MD
    Professor of Medicine
    Division of Hematology-Oncology
    Mayo Clinic, Jacksonville FL 

    Amrita Krishnan, MD
    Director of Judy and Bernard Briskin Multiple Myeloma Center
    Professor of Hematology/Hematopoietic Cell Transplantation
    Duarte, CA

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Sara Fagerlie, PHD, CHCP, has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Anna Trentini has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the mechanism of action and relevant targets for bispecific antibodies
    • Interpret results from clinical trials evaluating the treatment of relapsed/refractory multiple myeloma (RRMM) with bispecific antibodies
    • Describe mitigation strategies for bispecific antibody-related adverse events
    • Recognize outcomes for patients with triple-class refractory multiple myeloma (MM)
    • Address disparities in access to novel MM treatments
    • Identify patients who are candidates for immunotherapies
    • Mange treatment-related adverse events for patients undergoing therapy for multiple myeloma

  • Target Audience

    This activity is designed to meet the educational needs of community and academic medical oncologists, hematologist oncologists, and other healthcare professionals who manage patients with hematologic malignancies in the United States.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Live Satellite Symposium activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This event is organized by Prova Education, accredited by Global Learning Collaborative, Inc., and is supported by an educational grant provided by Janssen Biotech Inc., administered by Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Presenters

Related

  • ASCO MM

    BCMA Who and When: Immunotherapies in Patients with RRMM

    Show more

Facebook Comments

Recommended

Schedule7 Dec 2022
PrevNext

Segment Chapters

Playlist:

Recommended